Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months

Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months

Paul Regal, Balakrishnan Nair, Eileen Hetherington Geriatric Medicine and Gerontology, University of Newcastle, Callaghan, NSW, Australia Background: The purpose of this study was to compare apolipoprotein E ε4 (Apo E ε4) and apolipoprotein E ε2 (Apo E &epsil...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Regal P, Nair B, Hetherington E
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Apo E genotype
dementia
mild cognitive impairment
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/eaf088f09c294782859c3a41bc331c09
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:eaf088f09c294782859c3a41bc331c09
record_format dspace
spelling oai:doaj.org-article:eaf088f09c294782859c3a41bc331c092021-12-02T06:21:22ZApolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months1178-1998https://doaj.org/article/eaf088f09c294782859c3a41bc331c092013-11-01T00:00:00Zhttps://www.dovepress.com/apolipoprotein-e-epsilon4-is-superior-to-apolipoprotein-e-epsilon2-in--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Paul Regal, Balakrishnan Nair, Eileen Hetherington Geriatric Medicine and Gerontology, University of Newcastle, Callaghan, NSW, Australia Background: The purpose of this study was to compare apolipoprotein E ε4 (Apo E ε4) and apolipoprotein E ε2 (Apo E ε2) as predictors of cognitive and functional trajectories over 30 months. Methods: This prospective cohort study included 287 community-dwelling memory clinic patients with dementia, mild cognitive impairment, or no cognitive impairment. The Addenbrooke Cognitive Assessment, Mini-Mental State Examination, Montreal Cognitive Assessment, Delirium Index, and Nottingham Instrumental Activities of Daily Living tests were administered to each subject. Results: One hundred and nine subjects (40%) carried Apo E ε4 and 48 (16.7%) carried Apo E ε2. One hundred and nine ε4-positive subjects differed significantly from 178 ε4-negative subjects in 19/52 comparisons (36.5%), whereas 46 Apo E ε2-positive subjects had 0/52 significant differences from 239 ε2-negative subjects (P < 0.0001). The variables most affected by ε4 were the Delirium Index and Mini-Mental State Examination. Instrumental Activities of Daily Living score and residence were unrelated to Apo E ε4 or ε2. Conclusion: Apo E ε4 positivity predicted four cognitive scores measured every 6 months over 30 months. Apo E ε2 scores predicted none of 52 comparisons. Keywords: apolipoprotein E genotype, dementia, mild cognitive impairmentRegal PNair BHetherington EDove Medical PressarticleApo E genotypedementiamild cognitive impairmentGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 1461-1465 (2013)
institution DOAJ
collection DOAJ
language EN
topic Apo E genotype
dementia
mild cognitive impairment
Geriatrics
RC952-954.6
spellingShingle Apo E genotype
dementia
mild cognitive impairment
Geriatrics
RC952-954.6
Regal P
Nair B
Hetherington E
Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months
description Paul Regal, Balakrishnan Nair, Eileen Hetherington Geriatric Medicine and Gerontology, University of Newcastle, Callaghan, NSW, Australia Background: The purpose of this study was to compare apolipoprotein E ε4 (Apo E ε4) and apolipoprotein E ε2 (Apo E ε2) as predictors of cognitive and functional trajectories over 30 months. Methods: This prospective cohort study included 287 community-dwelling memory clinic patients with dementia, mild cognitive impairment, or no cognitive impairment. The Addenbrooke Cognitive Assessment, Mini-Mental State Examination, Montreal Cognitive Assessment, Delirium Index, and Nottingham Instrumental Activities of Daily Living tests were administered to each subject. Results: One hundred and nine subjects (40%) carried Apo E ε4 and 48 (16.7%) carried Apo E ε2. One hundred and nine ε4-positive subjects differed significantly from 178 ε4-negative subjects in 19/52 comparisons (36.5%), whereas 46 Apo E ε2-positive subjects had 0/52 significant differences from 239 ε2-negative subjects (P < 0.0001). The variables most affected by ε4 were the Delirium Index and Mini-Mental State Examination. Instrumental Activities of Daily Living score and residence were unrelated to Apo E ε4 or ε2. Conclusion: Apo E ε4 positivity predicted four cognitive scores measured every 6 months over 30 months. Apo E ε2 scores predicted none of 52 comparisons. Keywords: apolipoprotein E genotype, dementia, mild cognitive impairment
format article
author Regal P
Nair B
Hetherington E
author_facet Regal P
Nair B
Hetherington E
author_sort Regal P
title Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months
title_short Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months
title_full Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months
title_fullStr Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months
title_full_unstemmed Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months
title_sort apolipoprotein e ε4 is superior to apolipoprotein e ε2 in predicting cognitive scores over 30 months
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/eaf088f09c294782859c3a41bc331c09
work_keys_str_mv AT regalp apolipoproteineepsilon4issuperiortoapolipoproteineepsilon2inpredictingcognitivescoresover30months
AT nairb apolipoproteineepsilon4issuperiortoapolipoproteineepsilon2inpredictingcognitivescoresover30months
AT hetheringtone apolipoproteineepsilon4issuperiortoapolipoproteineepsilon2inpredictingcognitivescoresover30months
_version_ 1718399966996594688

Ejemplares similares